Count up to 2 but not beyond by Morley, S
This is a repository copy of Count up to 2 but not beyond.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/78820/
Version: Accepted Version
Article:
Morley, S (2014) Count up to 2 but not beyond. Pain. ISSN 0304-3959 
https://doi.org/10.1016/j.pain.2014.03.020
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright 
exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy 
solely for the purpose of non-commercial research or private study within the limits of fair dealing. The 
publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White 
Rose Research Online record for this item. Where records identify the publisher as the copyright holder, 
users can verify any specific terms of use on the publisher’s website. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
 1 
 
Editorial Commentary 
Accepted for Publication in Pain 2014 
 
 
ÔCount up to two but not beyondÕ1 
 
Stephen Morley 
University of Leeds 
 
 
Correspondence to 
Stephen Morley 
T: +44 113 343 2733 
E: s.j.morley@leeds.ac.uk 
Address 
Charles Thackrah Building, University of Leeds, 101 Clarendon Road, Leeds, LS2 9LJ, UK 
  
 2 
 
Psychologists have a strong preference for measuring human attributes (emotions, 
behavioral repertoires, cognitive appraisals) as dimensional continuities, routinely testing for 
differences with a Fisherian null hypothesis procedure to detect mean difference. The 
importance of that difference has often been of secondary concern.  There have been plenty of 
dissenting voices [1; 9; 20] but old habits die hard.  One consequence of this is that the 
evaluation of treatment effectiveness, at least since GlassÕs pioneering meta-analysis [14], has 
been expressed as an effect size: the magnitude of differences between two groups expressed as a 
ratio of their variance.  There are two points to note. First, the effect size is a statistical measure 
devoid of any additional meaning; in and of itself it has no external referent. Second, it is difficult 
to express the benefits of a treatment in a way that is readily understandable to patients or even 
to other stakeholders. An effect size of 0.8, an omnibus value for psychological treatments [19], 
is the 79th percentile of the control group.  An effect size of around 0.2, a current estimate for 
psychological treatments of pain corresponds to the 58th percentile [10]. This is difficult to 
communicate as it doesnÕt correspond to the patientÕs reasonable enquiry Ôhow many people get 
betterÕ.  In this case counting to two (ÔbetterÕ vs. Ônot betterÕ) might be a strategy to be preferred 
to divining subtle between group differences. 
Few trials of psychological interventions count to two.  Where they have done so, the 
tendency has been to dichotomize a continuous measure [16].  This problem is not unique to 
psychological measures. There is a copious literature on dichotomizing and categorizing 
continuous measures of pain.  Valid cut scores for mild, moderate, and severe pain are 
established by testing the association of pain scores with indices of functional performance [3; 5; 
12]. In this issue of PAIN Sil and colleagues [13] report a secondary analysis of trial data where 
the original hypothesis was that a CBT intervention would Ôbe significantly more effectiveÕ 
(p.298) than education in reducing the primary outcome of functional disability in children with 
juvenile fibromyalgia i.e., an hypothesis of difference in means [8]. The immediate post treatment 
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effect gave an impressive uncorrected effect size = 0.78 (data in Table 2 [8]), which is good in 
the context of similar trials [4]. 
Sil et al take a two stage approach to evaluating clinical significant by following 
JacobsonÕs methodology [6]. Step one establishes the magnitude of change required for the 
change to be beyond that attributable to measurement error. This smallest detectable value is a 
statistical criterion for measurement precision not a clinical criterion.  The setting of clinical 
criteria is more problematic and varied. JacobsonÕs method uses the statistical properties of the 
measure to set three possible cut points.   For two cut points data from a non-clinical reference 
sample is required.  The third cut point relies solely on the distribution of the clinical group.  
Each cut point categorizes the individual in reference to their relative position in the group.  The 
cut points are determined by statistical criteria intrinsic to the measure.  The validity of the 
interpretation depends on the likely assignment to group membership.  As such it may tell us 
little about other parameters likely to be of clinical or social importance e.g. probability of 
relapse.  
Sil et al take a slightly different approach to defining clinical significance for the 
Functional Disability Inventory (FDI).  They use cut points established in a prior analysis of data 
from 1300 children with a variety of pain disorders [7]. That study set cut points at the upper and 
lower quartiles of the distribution to give three groups (no/minimal, moderate and severe 
disability) validating the classification by correlating FDI scores with pain intensity.  This is 
somewhat ironic given the history of of validating pain scores by reference to function (supra).  
Arguably validation of a measure for clinical significance would be better established using 
operations of convergent validity i.e. other measures of function.)  Kashikar-Zuck et al [7] 
analysis of the FDI showed that mean disability increased with age and that there were slight 
differences between clinical groups in FDI score: information not used in Sil et alÕs analysis.  
There are many advantages in using the distributional properties of scales in outcome 
trials.  Our use of them would be aided by the development of high quality norms, including 
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parameters such as age, gender, diagnostic group (including non-clinical), and country, which 
capture known variation in data [11; 17].  Larger samples, obtained by combining data sets with 
meta-analytic techniques will give more accurate estimates and better prediction for individuals.  
The work of IMMPACT [2; 15; 18] has focused attention on the need rationalize the plethora of 
measures used and this should facilitate the selection of measures for further development.  
Validation, especially with regard to establishing meaningful clinical cut points i.e. those that 
enable us to make good clinical decisions, is an ongoing requirement.   We need to be able to 
count to two but we also need to capture the subtlety and variation in human behavior.    
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Footnote on the title 
1 The title is a quotation from George W PickeringÕs text (High Blood Pressure, 2nd edition, 
London:J&A Churchill, Ltd., 1968) and restated by the British epidemiologist Geoffrey Rose.  
See an imaginary, and enlightening, conversation between Rose and Socrates at:  
http://alertandoriented.com/geoffreyrosepart3/Rose - accessed 20 March 2014 
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